09 December 2021 : Database Analysis
Low Expression of Long Noncoding RNA SLC26A4 Antisense RNA 1 Is an Independent Prognostic Biomarker and Correlate of Immune Infiltrates in Breast Cancer
Weiwei Yi1ABCEF, Haiqing Shen2BC, Dexi Sun3BC, Yongchao Xu4BC, Yujie Feng1BC, Dongbing Li5BC, Caixia Wang1ABCEF*DOI: 10.12659/MSM.934522
Med Sci Monit 2021; 27:e934522
Table 1 The Cancer Genome Atlas-based characterization of patients with breast cancer.
| Characteristic | Levels | Overall |
|---|---|---|
| n | 1083 | |
| T stage, n (%) | T1 | 277 (25.6%) |
| T2 | 629 (58.2%) | |
| T3 | 139 (12.9%) | |
| T4 | 35 (3.2%) | |
| N stage, n (%) | N0 | 514 (48.3%) |
| N1 | 358 (33.6%) | |
| N2 | 116 (10.9%) | |
| N3 | 76 (7.1%) | |
| M stage, n (%) | M0 | 902 (97.8%) |
| M1 | 20 (2.2%) | |
| Pathologic stage, n (%) | Stage I | 181 (17.1%) |
| Stage II | 619 (58.4%) | |
| Stage III | 242 (22.8%) | |
| Stage IV | 18 (1.7%) | |
| Race, n (%) | Asian | 60 (6%) |
| Black or African American | 181 (18.2%) | |
| White | 753 (75.8%) | |
| Age, n (%) | ≤60 | 601 (55.5%) |
| >60 | 482 (44.5%) | |
| Histological type, n (%) | Infiltrating ductal carcinoma | 772 (79%) |
| Infiltrating lobular carcinoma | 205 (21%) | |
| PR status, n (%) | Negative | 342 (33.1%) |
| Indeterminate | 4 (0.4%) | |
| Positive | 688 (66.5%) | |
| ER status, n (%) | Negative | 240 (23.2%) |
| Indeterminate | 2 (0.2%) | |
| Positive | 793 (76.6%) | |
| HER2 status, n (%) | Negative | 558 (76.8%) |
| Indeterminate | 12 (1.7%) | |
| Positive | 157 (21.6%) | |
| PAM50, n (%) | Normal | 40 (3.7%) |
| LumA | 562 (51.9%) | |
| LumB | 204 (18.8%) | |
| Her2 | 82 (7.6%) | |
| Basal | 195 (18%) | |
| Menopause status, n (%) | Pre | 229 (23.6%) |
| Peri | 40 (4.1%) | |
| Post | 703 (72.3%) | |
| Anatomic neoplasm subdivisions, n (%) | Left | 563 (52%) |
| Right | 520 (48%) | |
| Radiation therapy, n (%) | No | 434 (44%) |
| Yes | 553 (56%) | |
| Age, median (IQR) | 58 (48.5, 67) |